SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Cardiovascular Drug Development
11 references·0 citing·36 second hop
Cardiovascular Drug Development (2015)Cardiovascular Drug DevelopmentScientific and Regulatory Reasons for Delay and Denial of FDA Approval of Initial Applications for New Drugs, 2000-2012 (2014)Scientific and Regulatory Rea…A Tale of Coronary Artery Disease and Myocardial Infarction (2012)A Tale of Coronary Artery Dis…The productivity crisis in pharmaceutical R&D (2011)The productivity crisis in ph…Accelerated Approval of Oncology Products: The Food and Drug Administration Experience (2011)Accelerated Approval of Oncol…Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs (2010)Trends in Risks Associated Wi…Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000–2009 (2010)Pharmaceutical Innovation in …Deconstructing the Drug Development Process: The New Face of Innovation (2010)Deconstructing the Drug Devel…Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma (2008)Balancing early market access…Projections of Global Mortality and Burden of Disease from 2002 to 2030 (2006)Projections of Global Mortali…Can the pharmaceutical industry reduce attrition rates? (2004)Can the pharmaceutical indust…Rating Banks: Risk and Uncertainty in an Opaque Industry (2002)Rating Banks: Risk and Uncert…The price of innovation: new estimates of drug development costs (2003)Diagnosing the decline in pharmaceutical R&D efficiency (2012)Clinical development success rates for investigational drugs (2014)Risks in new drug development: Approval success rates for investigational drugs (2001)The cost of biopharmaceutical R&D: is biotech different? (2007)Exploring different approaches to improve the success of drug discovery and development projects: a review (2020)The past, present and future of open innovation (2020)Modeling and Forecasting U. S. Mortality (1992)Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study (1997)Counting the dead and what they died from: an assessment of the global status of cause of death data. (2005)ASSOCIATION BETWEEN SOCIAL MEDIA USE AND DEPRESSION AMONG U.S. YOUNG ADULTS (2016)Future life expectancy in 35 industrialised countries: projections with a Bayesian model ensemble (2017)Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories (2018)Priority medicines for Europe and the world (2004)From efficacy to equity: Literature review of decision criteria for resource allocation and healthcare decisionmaking (2012)Regulatory Review of Novel Therapeutics — Comparison of Three Regulatory Agencies (2012)Protecting Their Intellectual Assets: Appropriability Conditions and Why U.S. Manufacturing Firms Patent (or Not) (2000)How to improve R&D productivity: the pharmaceutical industry's grand challenge (2010)Changing R&D models in research-based pharmaceutical companies (2016)A Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions (2021)How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment (2021)Lessons from 60 years of pharmaceutical innovation (2009)An overview of FDA-approved new molecular entities: 1827–2013 (2014)Theory of the firm: Managerial behavior, agency costs and ownership structure (1976)Agency Costs of Free Cash Flow, Corporate Finance, and Takeovers (1986)Agency costs of free cash flow, corporate finance, and takeovers (1996)Has Financial Development Made the World Riskier? (2005)Rethinking Bank Regulation: Till Angels Govern (2005)Has Finance Made the World Riskier? (2006)Learning from successes and failures in pharmaceutical R&D (2016)Clinician-Reported Outcome Assessments of Treatment Benefit: Report of the ISPOR Clinical Outcome Assessment Emerging Good Practices Task Force (2017)Challenges and opportunities of drug repositioning (2013)Killer Acquisitions (2020)Can Noncommunicable Diseases Be Prevented? Lessons from Studies of Populations and Individuals (2012)Best Care at Lower Cost (2013)Best care at lower cost: the path to continuously learning health care in America (2014)
this work references cited by second hop

References

  • 2006Projections of Global Mortality and Burden of Disease from 2002 to 203011,372 cited
  • 2004Can the pharmaceutical industry reduce attrition rates?4,167 cited
  • 2002Rating Banks: Risk and Uncertainty in an Opaque Industry1,244 cited
  • 2012A Tale of Coronary Artery Disease and Myocardial Infarction995 cited
  • 2011The productivity crisis in pharmaceutical R&D918 cited
  • 2010Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs847 cited
  • 2010Deconstructing the Drug Development Process: The New Face of Innovation422 cited
  • 2010Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000–2009329 cited
  • 2008Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma229 cited
  • 2014Scientific and Regulatory Reasons for Delay and Denial of FDA Approval of Initial Applications for New Drugs, 2000-2012214 cited
  • 2011Accelerated Approval of Oncology Products: The Food and Drug Administration Experience212 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work